Setting new standards in information exchange for the pharmaceutical and biotech industry
New Immunotherapy Drug Approved to Treat Non-Small Cell Lung Cancer
April 18, 2017
Merck’s SVP of Clinical Global Development, Dr Roy Baynes, and BMS’s VP, Head of US Medical and R&D, Dr Julie Hambleton will be sharing data on combination immunotherapy for Lung Cancer and emerging key combinations with pembrolizumab in late stage development at the 2nd annual Rational Combinations 360° program, June 28-29, in NYC.
Roche’s Tecentriq® (atezolizumab) joins BMS’s Opdivo® (nivolumab) and Merck’s Keytruda® (pembrolizumab) in treating certain patients with non-small cell lung cancer (NSCLC).
Roche received approval on Monday, April 17, 2017 to expand it’s use to treat patients with metastatic non small cell lung cancer (NSCLC) who are not eligible for standard cisplatin chemotherapy.
Atezolizumab was first approved in May 2016 for treating certain patients with urothelial carcinoma. With the expanded use approval, this now means there are three FDA approved immunotherapy treatment options for NSCLC.